📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-13 20:59
453 analysed today
453
Today
133,342
All-time analysed
40,106
Positive
6,279
Negative
79,144
Neutral
7,745
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
17 announcements match the current filters (relevance ≥ 5).
Banka BioLoo Q1 PAT up 162% to ₹0.37 Cr; Unexecuted Order Book reaches ₹82 Cr
Banka BioLoo reported a 20.5% YoY revenue growth to ₹16.40 Cr for Q1 FY26-27, with PAT rising 162% to ₹0.37 Cr. The company maintains a strong unexecuted order book of ₹82 Cr, which is approximately 144% of its TTM revenue, providing multi-quarter visibility. Its subsidiary, Megaliter Varunaa, has scaled to a ₹122 Cr Lifetime Value (LTV) across 15 projects, focusing on long-term water infrastructure. Despite the growth, the company remains a micro-cap with thin margins and a high P/E ratio.
Confidence: HIGH
What changedThe company has demonstrated a strong recovery in profitability and order book growth compared to the losses seen in FY25.
Why it mattersThe significant order book relative to the company's market cap and revenue suggests potential for a re-rating if execution remains consistent and margins improve.
Q1 Revenue: ₹16.40 CrUnexecuted Order Book: ₹82 CrOrder Book vs TTM Revenue: 143.8%Megaliter Net LTV: ₹122 CrQ1 PAT: ₹0.37 Cr
📅 Short termThe stock may see positive momentum due to the sharp YoY growth in PAT and the substantial unexecuted order book visibility.
📈 Long termThe structural shift toward long-term O&M and BOOT contracts in water infrastructure could provide more stable, recurring revenue over 7-10 year cycles.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High P/E ratio of 248.4
- Thin net profit margins
- High dependence on government and railway contracts
- Potential equity dilution from ESOPs
Key Highlights
Q1 FY26-27 Revenue grew 20.5% YoY to ₹16.40 Cr compared to ₹13.61 Cr in the previous year
Unexecuted order book stands at ₹82 Cr, representing ~1.44x the TTM revenue of ₹57 Cr
Net Profit (PAT) increased by 162.3% YoY to ₹37 Lakhs from ₹14 Lakhs
Subsidiary Megaliter Varunaa reached a cumulative Net Lifetime Value (LTV) of ₹122 Cr across 15 projects
Company services 25,000+ railway bio-toilet systems daily across 7 zones and 26 states
👀 What to Watch
Monitor the execution pace of the ₹82 Cr order book and the margin trajectory of the Megaliter Varunaa projects as they transition from early-stage to steady-state revenue recognition.
Banka BioLoo Q1 Revenue Falls 13% to ₹10.71 Cr; ₹7.39 Cr Govt Receivables Under Dispute
Banka BioLoo reported a weak Q1 FY27 with consolidated revenue declining 13.1% YoY to ₹10.71 Cr. The company swung to a marginal net loss of ₹0.04 Cr, compared to a break-even position in the same quarter last year. A significant concern for investors is the ₹7.39 Cr in trade receivables from government bodies like Swachha Andhra Corporation, which are currently under dispute but supported by an interim High Court order. The board also approved the re-appointment of the Managing Director and granted 16,000 ESOPs at face value.
Confidence: HIGH
What changedThe company reported a 13% YoY revenue decline and a shift to a net loss for Q1 FY27, while highlighting ₹7.39 Cr in disputed government receivables.
Why it mattersFor a micro-cap with a ₹99 Cr market cap, the inability to collect 13% of its annual revenue from government clients strains cash flows and limits growth capital.
Q1 Revenue: ₹10.71 CrYoY Revenue Growth: -13.1%Net Loss (Q1): ₹0.04 CrDisputed Receivables: ₹7.39 CrReceivables vs TTM Revenue: 12.96%ESOP Exercise Price: ₹10.00
📅 Short termExpect negative sentiment due to the earnings miss and the persistent uncertainty regarding the recovery of government dues.
📈 Long termLong-term stability depends on resolving the receivable dispute and diversifying the client base away from high-risk government contracts.
⚠ Risk flags
- Significant government receivables under dispute (₹7.39 Cr)
- Revenue contraction of 13% YoY
- High P/E valuation of 248x relative to current earnings
Key Highlights
Consolidated Revenue for Q1 FY27 stood at ₹10.71 Cr, down from ₹12.33 Cr in Q1 FY26.
Reported a Net Loss of ₹0.04 Cr for the quarter, compared to a marginal profit of ₹0.002 Cr in the year-ago period.
Trade receivables of ₹7.39 Cr from government bodies remain outstanding, representing approximately 13% of TTM revenue.
Board approved the re-appointment of Namita Sanjay Banka as Managing Director, subject to shareholder approval at the upcoming AGM.
Granted 16,000 ESOPs to employees at an exercise price of ₹10 per share, with a 4-year vesting schedule.
👀 What to Watch
Monitor the recovery of the ₹7.39 Cr government receivables and the impact of the new Labour Code on gratuity liabilities in upcoming quarters.
Banka BioLoo Reports Q1 FY27 Net Loss of ‹0.14 Cr; Revenue Drops 39% QoQ
Banka BioLoo Limited reported a consolidated net loss of ‹0.14 crore for Q1 FY27, a sharp reversal from the ‹1.60 crore profit in the preceding quarter. Revenue for the quarter stood at ‹10.71 crore, representing a 39% decline sequentially and a 13% drop year-on-year. A significant concern remains ‹7.38 crore in trade receivables from government bodies, which are currently under internal and legal review. The board also approved the grant of 16,000 ESOPs at a face value of ‹10 and the re-appointment of the Managing Director.
Confidence: HIGH
What changedThe company transitioned from a profitable quarter to a loss-making one, accompanied by a significant sequential revenue contraction.
Why it mattersThe sharp drop in revenue and the swing to a loss, combined with high P/E valuation (248x), suggests immediate pressure on the stock price and highlights risks in government-linked project execution.
Q1 FY27 Revenue: ‹10.71 crQ1 FY27 Net Loss: ‹0.14 crGovernment Receivables: ‹7.38 crReceivables vs TTM Revenue: ~13%ESOP Exercise Price: ‹10.00
📅 Short termThe stock may face downward pressure due to the weak quarterly performance and the shift back into losses.
📈 Long termLong-term sustainability depends on resolving receivable disputes and scaling the waste management business beyond government tenders.
⚠ Risk flags
- Significant trade receivables (‹7.38 cr) from government bodies under review
- High revenue volatility
- Swing to net loss
Key Highlights
Consolidated revenue fell to ‹10.71 crore in Q1 FY27 from ‹17.67 crore in Q4 FY26.
Swung to a net loss of ‹0.14 crore versus a profit of ‹1.60 crore in the previous quarter.
Trade receivables of ‹7.38 crore (approx. 13% of TTM revenue) from government bodies are under dispute/review.
Granted 16,000 ESOPs to employees at an exercise price of ‹10 per share.
14th Annual General Meeting (AGM) scheduled for September 17, 2026.
👀 What to Watch
Investors should monitor the recovery status of the ‹7.38 crore government receivables and observe if the company can stabilize its operating margins, which have been volatile.
Banka BioLoo Q1 FY27: Revenue Declines 12% YoY to Rs 10.71 Cr; Swings to Net Loss
Banka BioLoo reported a weak set of numbers for Q1 FY27, with consolidated revenue falling 12.3% YoY to Rs 10.71 Cr. The company swung to a consolidated net loss of Rs 3.93 Lakhs, a sharp decline from the Rs 1.60 Cr profit recorded in the preceding quarter (March 2026). A significant concern remains the Rs 7.38 Cr in trade receivables from government bodies, which is currently under discussion and represents approximately 21.7% of the company's net worth. The board also approved the re-appointment of Namita Sanjay Banka as Managing Director and granted 16,000 new ESOPs.
Confidence: HIGH
What changedThe company has transitioned from a profitable Q4 FY26 to a loss-making Q1 FY27, alongside a double-digit year-on-year revenue decline.
Why it mattersFor a micro-cap company with a Rs 99 Cr market cap, the combination of falling revenue and high government receivables (21.7% of net worth) creates significant working capital and valuation pressure.
Q1 FY27 Revenue: Rs 10.71 CrQ1 FY27 Net Loss: Rs 3.93 LakhsYoY Revenue Growth: -12.3%QoQ Revenue Growth: -39.8%Govt Receivables vs Net Worth: 21.7%
📅 Short termThe stock may face downward pressure in the short term due to the earnings miss and the swing from profit to loss.
📈 Long termLong-term sustainability depends on the company's ability to scale its waste management solutions and resolve persistent payment delays from government contracts.
⚠ Risk flags
- High government receivables concentration
- Significant sequential revenue volatility
- Micro-cap liquidity risk
Key Highlights
Consolidated revenue for Q1 FY27 stood at Rs 10.71 Cr, down from Rs 12.21 Cr in the same quarter last year.
Net loss of Rs 3.93 Lakhs reported for the quarter, compared to a profit of Rs 1.60 Cr in Q4 FY26.
Trade receivables of Rs 7.38 Cr from government bodies (CDMA and Swachha Andhra Corp) remain outstanding.
Granted 16,000 ESOPs at an exercise price of Rs 10 per share, vesting over a 4-year period.
Re-appointment of Promoter Namita Sanjay Banka as Managing Director approved, subject to AGM on Sept 17, 2026.
👀 What to Watch
Investors should monitor the recovery of the Rs 7.38 Cr government receivables and the company's ability to stabilize its top-line, which saw a nearly 40% sequential drop from the March 2026 quarter.
Banka BioLoo Redeems NCDs Worth Rs 4.30 Crore
Banka BioLoo Limited has successfully completed the redemption of 430 secured, unrated, and unlisted non-convertible debentures (NCDs). The total repayment amount stands at Rs 4.30 crore, with each unit valued at Rs 1,00,000. The company received a No Due Certificate on June 25, 2026, confirming that the facility was fully repaid on June 22, 2026. This debt reduction is expected to lower interest costs and improve the company's overall financial health.
Key Highlights
Redeemed 430 secured, unrated, and unlisted NCDs at par value.
Total aggregate value of the redemption is Rs 4.30 crore.
Full repayment confirmed by the Debenture Holder as of June 22, 2026.
Received official No Due Certificate dated June 24, 2026, confirming zero outstanding debt for this facility.
👀 What to Watch
Investors should view this as a positive sign of financial discipline and deleveraging. Monitor the company's upcoming quarterly results for improvements in net profit margins due to reduced interest outgo.
Banka BioLoo Reports FY26 Turnaround with ₹38.21 Lakh Profit vs ₹929.64 Lakh Loss in FY25
Banka BioLoo Limited has reported a significant financial turnaround for the fiscal year ended March 31, 2026, posting a net profit of ₹38.21 lakhs compared to a substantial loss of ₹929.64 lakhs in the previous year. Revenue from operations grew by 8.6% year-on-year to reach ₹5,975.76 lakhs. The fourth quarter was particularly strong, contributing ₹157.06 lakhs to the bottom line. However, investors should note an auditor's emphasis on ₹687.44 lakhs in trade receivables from government bodies, of which ₹125.26 lakhs have been outstanding for over two years without provision.
Key Highlights
Revenue from operations increased to ₹5,975.76 lakhs in FY26 from ₹5,500.03 lakhs in FY25
Achieved a net profit of ₹38.21 lakhs in FY26, recovering from a net loss of ₹929.64 lakhs in FY25
Q4 FY26 standalone profit stood at ₹157.06 lakhs compared to a loss of ₹172.90 lakhs in Q4 FY25
Earnings Per Share (EPS) improved to ₹0.35 from a negative ₹8.57 in the previous fiscal year
Auditors highlighted ₹687.44 lakhs in government receivables, with ₹125.26 lakhs overdue for more than two years
👀 What to Watch
The company has successfully moved from losses to profitability, which is a positive sign for recovery. Investors should monitor the collection of long-pending government receivables as any future provisioning could impact the bottom line.
Banka BioLoo Approves FY26 Audited Results; Receives Unmodified Audit Opinion
Banka BioLoo Limited has approved its audited standalone and consolidated financial results for the quarter and full year ending March 31, 2026. The statutory auditors, B. D. Saboo & Associates, issued an unmodified opinion, indicating that the financial statements present a true and fair view. The company also announced the appointment of a new Company Secretary and Internal Auditors for the 2026-2027 fiscal year. These administrative updates and the clean audit report demonstrate the company's commitment to regulatory compliance and corporate governance.
Key Highlights
Approved audited standalone and consolidated financial results for the year ended March 31, 2026.
Statutory auditors issued an unmodified/unqualified opinion on the financial results.
Appointed Ms. Srilakshmi Manjula Chaitanya Chunduru as Company Secretary and Compliance Officer.
Appointed M/s. SMAB & Associates as Internal Auditors for the financial year 2026-2027.
Updated and adopted amended policies for Whistle blower/Vigil mechanism and materiality disclosures.
👀 What to Watch
Investors should review the detailed financial tables on the company's website to assess specific growth and margin trends for FY26. The unmodified audit opinion provides confidence in the reported figures.
Banka BioLoo Q4 FY26 Turnaround: Revenue Up 29% YoY, PAT Positive at ₹1.57 Cr
Banka BioLoo reported a significant financial turnaround in Q4 FY26, with standalone revenue growing 29% YoY to ₹18.13 crore. The company moved from a net loss to a PAT of ₹1.57 crore for the quarter and achieved full-year profitability with a PAT of ₹38.2 lakh. The order book remains healthy at ₹107 crore, split between Railways (₹38 crore) and WaSH (₹69 crore) segments. Management highlighted geographic expansion into Mumbai and Bangalore and a shift towards higher-margin WaSH execution.
Key Highlights
Standalone Q4 revenue grew 29% YoY to ₹18.13 crore, while full-year revenue rose 10% to ₹61.01 crore.
Achieved a major turnaround with FY26 PAT of ₹38.2 lakh compared to a loss of ₹9.3 crore in FY25.
Total unexecuted order book stands at ₹107 crore, providing strong revenue visibility for the next fiscal year.
WaSH segment order booking for the year reached ₹56 crore, with new project wins from Grade-A developers like Reliance and Brigade.
EBITDA for Q4 FY26 turned positive at ₹2.54 crore versus a loss of ₹0.67 crore in the previous year's quarter.
👀 What to Watch
The company has successfully pivoted back to profitability after a difficult FY25, making it a recovery play in the sanitation and water treatment space. Investors should monitor the execution of the ₹107 crore order book and margin sustainability in the expanding WaSH segment.
Banka BioLoo Approves FY26 Audited Results; Appoints New CS and Internal Auditor
Banka BioLoo Limited has approved its audited standalone and consolidated financial results for the fiscal year ended March 31, 2026. The statutory auditors issued an unmodified opinion, confirming the reliability of the financial statements. The company also announced the appointment of Ms. Srilakshmi Manjula Chaitanya Chunduru as Company Secretary and Compliance Officer. Furthermore, M/s. SMAB & Associates were appointed as Internal Auditors for FY 2026-27 to enhance internal control frameworks.
Key Highlights
Approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Statutory auditors B. D. Saboo & Associates issued an unmodified/unqualified opinion on the FY26 results.
Appointed Ms. Srilakshmi Manjula Chaitanya Chunduru as Company Secretary and Compliance Officer effective May 26, 2026.
Appointed M/s. SMAB & Associates as Internal Auditors for the financial year 2026-2027.
Updated corporate governance policies including the Whistleblower/Vigil mechanism and materiality disclosure protocols.
👀 What to Watch
Investors should examine the full FY26 financial statements to evaluate the company's operational performance and growth. The unmodified audit opinion is a positive indicator of the company's financial reporting integrity.
Banka BioLoo Approves FY26 Audited Results and Appoints New Company Secretary
Banka BioLoo's Board has approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The statutory auditors issued an unmodified opinion, indicating no major accounting discrepancies. In a key management change, Ms. Srilakshmi Manjula Chaitanya Chunduru was appointed as the Company Secretary and Compliance Officer effective May 26, 2026. Additionally, the firm appointed SMAB & Associates as Internal Auditors for FY 2026-27 and updated its corporate governance policies.
Key Highlights
Approved audited standalone and consolidated financial results for the year ended March 31, 2026
Statutory auditors B. D. Saboo & Associates provided an unmodified/unqualified audit opinion
Appointed Ms. Srilakshmi Manjula Chaitanya Chunduru as Company Secretary and Compliance Officer
Appointed SMAB & Associates as Internal Auditors for the 2026-2027 financial year
Adopted amended policies for Whistleblower/Vigil mechanism and materiality of event disclosures
👀 What to Watch
Investors should examine the full financial statements on the exchange for specific revenue and profit trends. The unmodified audit opinion and regular KMP appointments suggest stable corporate governance.
Banka BioLoo Approves FY26 Audited Results; Appoints New CS and Internal Auditors
Banka BioLoo's Board approved the audited financial results for the quarter and fiscal year ended March 31, 2026, with an unmodified audit opinion. The company appointed Ms. Srilakshmi Manjula Chaitanya Chunduru as the new Company Secretary and Compliance Officer effective May 26, 2026. Furthermore, SMAB & Associates were designated as internal auditors for the upcoming 2026-2027 fiscal year. The board also updated internal governance policies, including the whistle-blower mechanism and materiality disclosure authorizations.
Key Highlights
Approved audited standalone and consolidated financial results for the fiscal year ended March 31, 2026.
Statutory auditors B. D. Saboo & Associates issued an unmodified/unqualified opinion on the FY26 results.
Appointed Ms. Srilakshmi Manjula Chaitanya Chunduru as Company Secretary and Compliance Officer effective May 26, 2026.
Engaged M/s. SMAB & Associates as Internal Auditors for the 2026-2027 financial year.
Amended and adopted updated policies for Whistle blower/Vigil mechanism and materiality disclosures.
👀 What to Watch
Investors should review the detailed FY26 financial statements on the company's website to assess operational performance. The management and auditor appointments are routine governance updates and do not signal immediate structural changes.
Banka BioLoo Approves FY26 Audited Results with Unmodified Audit Opinion
Banka BioLoo's Board has approved the audited standalone and consolidated financial results for the quarter and full year ending March 31, 2026. The statutory auditors, B. D. Saboo & Associates, provided an unmodified opinion, indicating the financial statements are presented fairly in all material respects. The company also announced the appointment of a new Company Secretary and Compliance Officer, alongside a new Internal Auditor for FY 2026-27. These administrative updates and policy amendments ensure continued compliance with SEBI listing regulations.
Key Highlights
Approved audited standalone and consolidated financial results for the fiscal year ended March 31, 2026.
Statutory auditors issued an unmodified/unqualified opinion on the financial results.
Appointed Ms. Srilakshmi Manjula Chaitanya Chunduru as Company Secretary and Compliance Officer effective May 26, 2026.
Appointed SMAB & Associates as Internal Auditors for the financial year 2026-2027.
Approved and adopted amended policies for Whistleblower/Vigil mechanism and Materiality of events.
👀 What to Watch
Investors should review the full financial statements on the company's website to evaluate revenue and profit growth trends for FY26. The unmodified audit opinion is a positive sign of transparent financial reporting and corporate governance.
Banka BioLoo Approves FY26 Audited Results and Appoints New Company Secretary
Banka BioLoo Limited has approved its audited standalone and consolidated financial results for the quarter and full year ended March 31, 2026. The statutory auditors issued an unmodified opinion, indicating that the financial statements present a true and fair view of the company's affairs. In addition to the results, the board appointed Ms. Srilakshmi Manjula Chaitanya Chunduru as the Company Secretary and Compliance Officer. The company also designated SMAB & Associates as Internal Auditors for the 2026-27 fiscal year to strengthen corporate governance.
Key Highlights
Approved audited standalone and consolidated financial results for the fiscal year ended March 31, 2026.
Statutory auditors B. D. Saboo & Associates issued an unmodified/unqualified opinion on the financial results.
Appointed Ms. Srilakshmi Manjula Chaitanya Chunduru as Company Secretary and Compliance Officer effective May 26, 2026.
Appointed M/s. SMAB & Associates as Internal Auditors for the financial year 2026-2027.
Updated and approved policies regarding Whistle blower/Vigil mechanism and materiality of events.
👀 What to Watch
Investors should review the detailed financial performance metrics once the full report is published to assess growth trends. The unmodified audit opinion is a positive indicator of financial reporting integrity.
Banka BioLoo to Provide Rs 10 Crore Corporate Guarantee for Subsidiary Megaliter Varunaa
Banka BioLoo Limited has approved the issuance of a corporate guarantee to secure credit facilities for its subsidiary, Megaliter Varunaa Private Limited. The guarantee covers an amount up to Rs 10 Crores in favor of Northern Arc Capital Limited. This commitment is unconditional and irrevocable, lasting until the subsidiary fully discharges its debt obligations. While it creates a contingent liability on a standalone basis, the company notes there is no impact on consolidated financials.
Key Highlights
Corporate guarantee issued for subsidiary Megaliter Varunaa Private Limited for up to Rs 10 Crores
Credit facility to be provided by lender Northern Arc Capital Limited in one or more tranches
Guarantee is unconditional and irrevocable, covering principal, interest, and other charges
Transaction is at arm's length, though the parent company is a promoter of the borrower
The guarantee will be recorded as a contingent liability on the standalone balance sheet
👀 What to Watch
Investors should monitor the subsidiary's ability to service its debt, as a default would impact the parent company's standalone financials. No immediate action is necessary as this is a standard corporate support mechanism.
Banka BioLoo Q3 FY26: Revenue Up 15% YoY, EBITDA Turns Positive at ₹90 Lakhs
Banka BioLoo reported a 15% YoY growth in standalone gross sales revenue to ₹18.78 crore for Q3 FY26. The company achieved a significant operational turnaround with standalone EBITDA rising to ₹90 lakh from a loss of ₹33.6 lakh in the previous year, driven by cost optimization and increased execution in the WaSH segment. While the company still reported a consolidated net loss of ₹12.45 lakh, it is a substantial improvement from the ₹145.54 lakh loss in Q3 FY25. The total unexecuted order book remains robust at ₹113 crore, providing strong revenue visibility.
Key Highlights
Standalone Gross Sales Revenue increased by 15% YoY to ₹18.78 crore in Q3 FY26.
Standalone EBITDA turned positive at ₹90 lakh, reflecting a ~373% increase from the previous year's loss.
Total unexecuted order book stands at ₹113 crore, split between Railways (₹49.5 cr) and WaSH (₹63.5 cr).
New order wins in the WaSH segment totaled ₹14.64 crore during Q3, including expansion into Mumbai and Bangalore.
Consolidated net loss narrowed significantly to ₹12.45 lakh from ₹145.54 lakh in the same quarter last year.
👀 What to Watch
Investors should monitor the company's ability to maintain EBITDA margins as it executes its ₹113 crore order book. The shift towards the WaSH segment and expansion into new geographies like Mumbai and Bangalore are positive indicators for long-term growth.
Banka BioLoo Q3 FY26: Revenue Grows to ₹15.93 Cr, Net Loss Narrows Significantly to ₹0.22 Cr
Banka BioLoo reported a revenue of ₹15.93 crore for Q3 FY26, up from ₹14.19 crore in the same quarter last year. The company significantly narrowed its net loss to ₹0.22 crore from a loss of ₹1.46 crore YoY, indicating improved operational efficiency. Total expenses for the quarter stood at ₹16.22 crore, with material costs being the largest component at ₹5.71 crore. While the company remains loss-making on a nine-month basis with a loss of ₹1.19 crore, the quarterly trend shows a strong recovery toward break-even.
Key Highlights
Revenue from operations increased by 12.3% YoY to ₹15.93 crore from ₹14.19 crore
Quarterly net loss narrowed by 85% YoY to ₹0.22 crore compared to ₹1.46 crore
Nine-month total income reached ₹42.88 crore, showing steady growth over the previous year
Earnings Per Share (EPS) improved to (0.20) for the quarter, up from (1.35) in Q3 FY25
Finance costs for the quarter were ₹0.66 crore, showing a slight decrease from ₹0.72 crore YoY
👀 What to Watch
The narrowing of losses and steady revenue growth are encouraging signs of a potential turnaround. Investors should monitor the company's ability to achieve net profitability in the upcoming quarters before increasing exposure.
Banka BioLoo Q3 Results: Revenue Up 12% YoY to ₹15.93 Cr, Net Loss Narrows to ₹0.22 Cr
Banka BioLoo reported a standalone revenue of ₹15.93 crore for the quarter ended December 31, 2025, marking a 12.3% increase from ₹14.19 crore in the same period last year. The company significantly narrowed its net loss to ₹0.22 crore, compared to a loss of ₹1.46 crore in Q3 FY25 and ₹1.10 crore in the preceding quarter. For the nine-month period, revenue grew to ₹42.73 crore, while the net loss reduced sharply to ₹1.19 crore from ₹7.57 crore in the previous year. This performance indicates a strong recovery trend and improved operational efficiency.
Key Highlights
Standalone revenue for Q3 FY26 grew 12.3% YoY to ₹15.93 crore from ₹14.19 crore.
Net loss narrowed significantly to ₹22.01 lakhs from ₹146.45 lakhs in the year-ago quarter.
9-month standalone revenue reached ₹42.73 crore, up from ₹40.92 crore in 9M FY25.
9-month net loss reduced to ₹1.19 crore compared to a substantial loss of ₹7.57 crore in the previous year.
Total expenses for the quarter stood at ₹16.22 crore, slightly higher than ₹15.82 crore in Q3 FY25.
👀 What to Watch
The consistent narrowing of losses and steady revenue growth suggest a potential turnaround for the company. Investors should watch for the company to achieve break-even and sustained profitability in the upcoming quarters before increasing exposure.
